Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Parkinson's Disease
66%
Parkinson's Progression Markers Initiative
18%
Mild Cognitive Impairment
17%
Idiopathic Parkinson's Disease
17%
Parkinson
16%
Risk Factors
14%
GBA1
11%
Levodopa-induced Dyskinesia
11%
Risk Variant
11%
Alpha-synuclein (α-syn)
11%
Mixed Model Analysis
11%
Gut Microbiota
11%
Longitudinal Mixed Model
11%
At-risk
11%
Non-motor Symptoms
10%
Luxembourg
10%
Disease Duration
8%
Non-carriers
8%
Clinical Progression
8%
Machine Learning
7%
Hyposmia
7%
Clinical Data
7%
Seed Amplification Assay
7%
Unified Parkinson's Disease Rating Scale (UPDRS)
7%
Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD)
6%
Parkinson Patients
6%
GBA1 Variant
6%
Procedural Memory
6%
Luxembourgish
6%
Freezing of Gait
6%
Leucine-rich Repeat Kinase 2 (LRRK2)
6%
Senior Authors
5%
Dopaminergic Pathway
5%
Long-read Sequencing
5%
Cardiovascular History
5%
Prognostic Analysis
5%
Data Management
5%
Cross-cohort
5%
Kassel
5%
Authorship Criteria
5%
Metabolomics Data
5%
Outcome Prediction
5%
Gait Data
5%
Clinical Decision Support Tool
5%
Serum Neurofilament Light Chain
5%
Seed Amplification
5%
SNCA mutation
5%
Chain Level
5%
Virtual Research Environment
5%
Mutation Data
5%
Neuroscience
Parkinson's Disease
100%
Mild Cognitive Impairment
19%
Freezing Of Gait
12%
Cognitive Disorders
12%
L-DOPA
12%
Dyskinesia
11%
Gut Microbiome
11%
Risk Factor
9%
Hyposmia
8%
Comorbidity
8%
Progressive Supranuclear Palsy
8%
Non-Motor Symptoms
7%
Atypical Parkinsonism
7%
Gait
7%
Synuclein
6%
Procedural Memory
6%
Memory Disorder
5%
Rapid Eye Movement Sleep
5%
Behavior Disorder
5%
MicroRNA
5%
Endophenotype
5%
Neurofilament Light Chain
5%
Alpha-Synuclein
5%
Diffusion MRI
5%
Cardiovascular System
5%
Dopamine
5%
Stereotypic Movement Disorder
5%
Medicine and Dentistry
Parkinson's Disease
45%
Gait
13%
Metabolomics
11%
Education
6%
Gut Microbiome
5%
Atypical Parkinsonism
5%
Infection
5%
Mild Cognitive Impairment
5%
Observational Study
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
COVID-19
5%
Mixed Model
5%
Dopamine
5%
Armin
5%
Levodopa-Induced Dyskinesia
5%
Cardiovascular System
5%
Aging brain
5%
Myelodysplastic Syndrome
5%
Unified Parkinson's Disease Rating Scale
5%
Comorbidity
5%